Global Cooperation Feasibility Studies

全球合作可行性研究

• 批准号: 132600
• 金额: $ 2.68万
• 依托单位: SACCADE DIAGNOSTICS LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=132600
• 关键词: Global; Cooperation; Feasibility; Studies

1 in 5 of us experience mental health problems during our lifetime but more than 50% of patients don’t receiveadequate care when assessed using current methods - leading to risk of further deterioration in well-being,reduction in quality of life, loss of income, family breakdown, and self-harming. SaccScan is a novel point-of-care (PoC) software diagnostic system which has been demonstrated to detect schizophrenia with better than95% accuracy and has been extended with the same precision to bipolar disorder and major depressionillnesses. The software diagnostic tool successfully utilises eye-movement abnormalities as clinical diagnosticbiomarkers for serious mental illnesses. The test can be performed within 30 minutes and results producedover the internet at near real-time speed. The purpose of this study is to explore international partnerships forbringing a minimum viable version of the test to market and address the global challenge of improvingtreatment outcomes through personalising medicine in mental health care.

我们中有五分之一的人在一生中经历过精神健康问题，但超过50%的患者在使用现有方法进行评估时没有得到充分的护理，从而导致福祉进一步恶化、生活质量下降、收入损失、家庭破裂和自我伤害的风险。sacscan是一种新型的即时护理（PoC）软件诊断系统，已被证明检测精神分裂症的准确率超过95%，并已扩展到双相情感障碍和重度抑郁症。该软件诊断工具成功地利用眼动异常作为严重精神疾病的临床诊断生物标志物。测试可以在30分钟内完成，结果以接近实时的速度在互联网上产生。本研究的目的是探索国际合作伙伴关系，将最低可行版本的测试推向市场，并解决通过个性化药物改善精神卫生保健治疗结果的全球挑战。